• Japanese
  • Korean
  • Chinese
Cover Image

Pharmacogenomics Partnering Terms and Agreements

The Pharmacogenomics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the pharmacogenomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 140 links to online copies of actual pharmacogenomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of pharmacogenomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in pharmacogenomics dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading pharmacogenomics deals since 2007. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top big pharma companies with a brief summary followed by a comprehensive listing of pharmacogenomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of pharmacogenomics partnering deals signed and announced since January 2007. The chapter is organized by specific pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in pharmacogenomics partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of pharmacogenomics technologies and products.

Pharmacogenomics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to pharmacogenomics trends and structure of deals entered into by leading companies worldwide.

Pharmacogenomics Partnering Terms and Agreements includes:

  • Trends in pharmacogenomics dealmaking in the biopharma industry since 2007
  • Analysis of pharmacogenomics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life pharmacogenomics deals
  • Access to over 140 pharmacogenomics contract documents
  • The leading pharmacogenomics deals by value since 2007
  • Most active pharmacogenomics dealmakers since 2007
  • The leading pharmacogenomics partnering resources

In Pharmacogenomics Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Report scope

The Pharmacogenomics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 140 pharmacogenomics deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise pharmacogenomisc rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Pharmacogenomics Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of pharmacogenomics deal trends since 2007
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of pharmacogenomics agreements with numerous real life case studies
  • Access to over 140 pharmacogenomics online deals entered into by the world's biopharma companies
  • Detailed access to actual pharmacogenomics contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a pharmacogenomics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in pharmacogenomics dealmaking

  • 2.1. Introduction
  • 2.2. Pharmacogenomicss partnering over the years
  • 2.3. Big pharma pharmacogenomics dealmaking activity
  • 2.4. Most active pharmacogenomicss dealmakers
  • 2.5. Pharmacogenomics partnering by deal type
  • 2.6. Pharmacogenomics partnering by disease type
  • 2.7 Average deal terms for pharmacogenomicss
    • 2.7.1 Pharmacogenomics headline values
    • 2.7.2 Pharmacogenomics upfront payments
    • 2.7.3 Pharmacogenomics milestone payments
    • 2.7.4 Pharmacogenomics royalty rates

Chapter 3 - Leading pharmacogenomics deals

  • 3.1. Introduction
  • 3.2. Top pharmacogenomics deals by value

Chapter 4 - Big pharma pharmacogenomics deals

  • 4.1. Introduction
  • 4.2. How to use big pharma pharmacogenomics partnering deals
  • 4.3. Bigpharma pharmacogenomics partnering company profiles
    • Abbott
    • AstraZeneca
    • Bayer
    • Eli Lilly
    • GlaxoSmithKline
    • Johnson & Johnson
    • Novartis
    • Pfizer
    • Roche
    • Takeda

Chapter 5 - Pharmacogenomics dealmaking directory

  • 5.1. Introduction
  • 5.2. Company A-Z
  • 5.3. By stage of development
    • Discovery
    • Marketed
    • Phase I
    • Phase II
    • Preclinical
  • 5.4. By deal type
    • Asset purchase
    • Co-development
    • Collaborative R&D
    • Contract service
    • Development
    • Distribution
    • Equity purchase
    • Evaluation
    • Grant
    • Joint venture
    • Licensing
    • Manufacturing
    • Marketing
    • Option
    • Promotion
    • Research
    • Supply
  • 5.5. By therapy area
    • Cardiovascular
    • Central Nervous System
    • Dermatology
    • Gastrointestinal
    • Genetic disorders
    • Hematology
    • Hospital care
    • Immunology
    • Infectives
    • Metabolic
    • Musculoskeletal
    • Oncology
    • Pediatrics
    • Psychiatry
    • Public Health
    • Respiratory

Chapter 6 -Pharmacogenomics dealmaking by technology type

  • 6.1. Introduction
  • 6.2. Deals by pharmacogenomics type
    • Pharmacogenomics

Chapter 7 - Pharmacogenomics partnering resource center

  • 7.1. Online pharmacogenomics partnering
  • 7.2. Pharmacogenomics partnering events
  • 7.3. Further reading on pharmacogenomics dealmaking

Appendices

  • Appendix 1 - Deal type definitions
  • Appendix 2 - Example pharmacogenomics partnering agreement
    • About Wildwood Ventures
    • Current Partnering
    • Current Agreements

Recent titles from CurrentPartnering

Order Form - Reports

Order Form - Therapy Reports

Table of figures

  • Figure 1: Pharmacogenomics partnering since 2007
  • Figure 2: Bigpharma pharmacogenomicss deal frequency - 2007 to 2013
  • Figure 3: Active pharmacogenomicss dealmaking activity- 2007 to 2013
  • Figure 4: Pharmacogenomics partnering by deal type since 2007
  • Figure 5: Pharmacogenomics partnering by disease type since 2007
  • Figure 6: Pharmacogenomics partnering by oncology target since 2007
  • Figure 7: Pharmacogenomics deals with a headline value
  • Figure 8: Pharmacogenomics deal headline value distribution, US$million - Discovery
  • Figure 9: Pharmacogenomics deal headline value distribution, US$million - Preclinical
  • Figure 10: Pharmacogenomics deal headline value distribution, US$million - Marketed
  • Figure 11: Pharmacogenomics deals with upfront payment values
  • Figure 12: Pharmacogenomics deal upfront payment distribution, US$million- Preclinical
  • Figure 13: Pharmacogenomics deals with milestone payments
  • Figure 14: Top pharmacogenomics deals by value since 2007
  • Figure 15: Pharmacogenomics deals by cardiovascular therapy type
  • Figure 16: Pharmacogenomics deals by CNS therapy type
  • Figure 17: Pharmacogenomics deals by Dermatology therapy type
  • Figure 18: Pharmacogenomics deals by gastrointestinal therapy type
  • Figure 19: Pharmacogenomics deals by genetic disorders therapy type
  • Figure 20: Pharmacogenomics deals by hematology therapy type
  • Figure 21: Pharmacogenomics deals by hospital care therapy type
  • Figure 22: Pharmacogenomics deals by immunology therapy type
  • Figure 23: Pharmacogenomics deals by infectives therapy type
  • Figure 24: Pharmacogenomics deals by metabolic therapy type
  • Figure 25: Pharmacogenomics deals by musculoskeletal therapy type
  • Figure 26: Pharmacogenomics deals by oncology therapy type
  • Figure 27: Pharmacogenomics deals by pediatrics therapy type
  • Figure 28: Pharmacogenomics deals by psychiatry therapy type
  • Figure 29: Pharmacogenomics deals by public health therapy type
  • Figure 30: Pharmacogenomics deals by respiratory therapy type
  • Figure 31: Online partnering resources
  • Figure 32: Forthcoming partnering events
  • Figure 33: Deal type definitions
  • Figure 34: Pharmacogenomics partnering agreement between GlaxoSmithKline and Response Genetics, May 2010
Show More
Pricing
Get Notified
Email me when related reports are published